Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Breaking down the barriers: challenges with development and implementation of an industry-sponsored antimicrobial stewardship data collection and analysis tool.

Hermsen ED, McDaneld PM, Eiland EH 3rd, Destache CJ, Lusardi K, Estrada SJ, Mercier RC, DePestel DD, Lamp KC, Anderson E, Chung TJ, McKinnon PS.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S179-84. doi: 10.1093/cid/ciu539.

PMID:
25261545
2.

Outcomes and metrics for antimicrobial stewardship: survey of physicians and pharmacists.

Bumpass JB, McDaneld PM, DePestel DD, Lamp KC, Chung TJ, McKinnon PS, Crompton MG, Hermsen ED.

Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S108-11. doi: 10.1093/cid/ciu545.

PMID:
25261537
3.

Optimizing delivery of care for patients with MRSA infection: focus on transitions of care.

McKinnon PS, Boening AJ, Amin AN.

Hosp Pract (1995). 2011 Apr;39(2):18-31. doi: 10.3810/hp.2011.04.391.

PMID:
21576894
4.

Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia.

Neuner EA, Casabar E, Reichley R, McKinnon PS.

Diagn Microbiol Infect Dis. 2010 Jul;67(3):228-33. doi: 10.1016/j.diagmicrobio.2010.02.026.

PMID:
20542203
5.

Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients.

Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, Ritchie DJ, Westervelt P, Dubberke ER.

Pharmacotherapy. 2010 Jun;30(6):554-61. doi: 10.1592/phco.30.6.554.

6.

Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.

Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.

Pharmacotherapy. 2009 Aug;29(8):914-23. doi: 10.1592/phco.29.8.914.

7.

Improving adherence to dyslipidemia medication guidelines in hospitalized diabetic patients using a technology-assisted pharmacist intervention.

McKinnon PS, Seaton T, Noirot LA, Reichley RM, Heard KM, Shannon WD, Goldberg AC, Dunagan WC, Bailey TC.

AMIA Annu Symp Proc. 2008 Nov 6:868.

PMID:
18999065
8.

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

McKinnon PS, Paladino JA, Schentag JJ.

Int J Antimicrob Agents. 2008 Apr;31(4):345-51. doi: 10.1016/j.ijantimicag.2007.12.009. Epub 2008 Mar 4.

PMID:
18313273
9.

Early clinical experience with anidulafungin at a large tertiary care medical center.

Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ.

Pharmacotherapy. 2008 Jan;28(1):64-73.

PMID:
18154476
10.

Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital.

Patel GW, Duquaine SM, McKinnon PS.

Pharmacotherapy. 2007 Dec;27(12):1637-43.

PMID:
18041884
11.

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.

Davis SL, McKinnon PS, Hall LM, Delgado G Jr, Rose W, Wilson RF, Rybak MJ.

Pharmacotherapy. 2007 Dec;27(12):1611-8.

PMID:
18041881
12.

Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ.

Antimicrob Agents Chemother. 2007 Oct;51(10):3731-3. Epub 2007 Jul 30.

13.

Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes.

Lodise TP Jr, McKinnon PS.

Pharmacotherapy. 2007 Jul;27(7):1001-12. Review.

PMID:
17594206
14.

Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.

Davis SL, Vazquez JA, McKinnon PS.

Ann Pharmacother. 2007 Apr;41(4):568-73. Epub 2007 Mar 20.

PMID:
17374623
15.

The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.

McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y.

Manag Care Interface. 2007 Jan;20(1):23-34. Erratum in: Manag Care Interface. 2007 Apr;20(4):27.

PMID:
17310650
16.

Adherence to dyslipidemia treatment guidelines in diabetic patients.

Reichley R, McKinnon PS, Seaton T, Noirot L, Dunagan WC, Bailey TC.

AMIA Annu Symp Proc. 2006:1071.

17.

Prospective validation of an algorithm to identify hospitalized diabetic patients using administrative data.

McKinnon PS, Reichley RM, Noirot LA, Dunagan WC, Bailey TC.

AMIA Annu Symp Proc. 2006:1029.

18.

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.

Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH.

Chest. 2006 Oct;130(4):947-55.

PMID:
17035423
19.

Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus.

Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS.

Infect Control Hosp Epidemiol. 2006 Oct;27(10):1025-31. Epub 2006 Sep 19.

PMID:
17006808
20.

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.

McKinnon PS, Sorensen SV, Liu LZ, Itani KM.

Ann Pharmacother. 2006 Jun;40(6):1017-23. Epub 2006 May 23.

PMID:
16720705
21.

Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies.

Lodise TP Jr, Rhoney DH, Tam VH, McKinnon PS, Drusano GL.

Diagn Microbiol Infect Dis. 2006 Mar;54(3):223-30. Epub 2006 Jan 19.

PMID:
16423490
22.

A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.

Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC.

Pharmacotherapy. 2005 Oct;25(10):1303-9.

PMID:
16185173
23.

Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia.

DeRyke CA, Lodise TP Jr, Rybak MJ, McKinnon PS.

Chest. 2005 Sep;128(3):1414-22.

PMID:
16162737
24.

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia.

Lodise TP, McKinnon PS.

Diagn Microbiol Infect Dis. 2005 Jun;52(2):113-22.

PMID:
15964499
25.

Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia.

Davis SL, Delgado G Jr, McKinnon PS.

Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S136-43.

PMID:
15942880
26.

Improving adherence with antimicrobial therapy for respiratory tract infections: a discussion of directly observed therapy (DOT) and short-course therapies.

Schwartz DB, Adler A, Dasaro AP, DeBellis RJ, Dick R, Ferro TJ, Krekun S, Malina RL, McKinnon PS, Volturo G.

Am J Ther. 2004 Jul-Aug;11 Suppl 1:S18-21.

PMID:
23570158
27.

Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model.

Shah NP, Reddy P, Paladino JA, McKinnon PS, Klepser ME, Pashos CL.

Curr Med Res Opin. 2004 Jun;20(6):779-90.

PMID:
15200734
28.

Pharmacologic considerations in antimicrobial therapy, with emphasis on pharmacokinetics and pharmacodynamics: reviews for the practicing clinician.

McKinnon PS, Yu VL.

Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):231-2. Epub 2004 Mar 13. Review. No abstract available.

PMID:
15024627
29.

Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

McKinnon PS, Davis SL.

Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):271-88. Epub 2004 Mar 10. Review.

PMID:
15015030
30.

An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW.

Pharmacoeconomics. 2003;21(18):1331-40.

PMID:
14750900
31.

Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance.

Lodise TP Jr, McKinnon PS, Rybak M.

Infect Control Hosp Epidemiol. 2003 Sep;24(9):655-61.

PMID:
14510247
32.

Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients.

Kanji S, McKinnon PS, Barletta JF, Kruse JA, Devlin JW.

Crit Care Med. 2003 May;31(5):1347-52.

PMID:
12771601
33.

Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.

Lodise TP, McKinnon PS, Swiderski L, Rybak MJ.

Clin Infect Dis. 2003 Jun 1;36(11):1418-23. Epub 2003 May 20.

PMID:
12766837
34.

Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.

Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ.

Antimicrob Agents Chemother. 2003 Jun;47(6):1853-61.

35.

Disposition of cefepime in the central nervous system of patients with external ventricular drains.

Rhoney DH, Tam VH, Parker D Jr, McKinnon PS, Coplin WM.

Pharmacotherapy. 2003 Mar;23(3):310-4.

PMID:
12627928
36.

Pharmacodynamics of cefepime in patients with Gram-negative infections.

Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL.

J Antimicrob Chemother. 2002 Sep;50(3):425-8.

PMID:
12205070
37.

Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center.

Lodise TP, McKinnon PS, Tam VH, Rybak MJ.

Clin Infect Dis. 2002 Apr 1;34(7):922-9. Epub 2002 Mar 4.

PMID:
11880957
38.

Cost perspectives for outpatient intravenous antimicrobial therapy.

Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E.

Pharmacotherapy. 2002 Feb;22(2 Pt 2):63S-70S.

PMID:
11837549
39.

Temporal assessment of Candida risk factors in the surgical intensive care unit.

McKinnon PS, Goff DA, Kern JW, Devlin JW, Barletta JF, Sierawski SJ, Mosenthal AC, Gore P, Ambegaonkar AJ, Lubowski TJ.

Arch Surg. 2001 Dec;136(12):1401-8; discussion 1409.

PMID:
11735868
40.
41.

New antibiotics for infections caused by resistant organisms.

McKinnon PS, Tam VH.

Support Care Cancer. 2001 Jan;9(1):8-10.

PMID:
11147147
42.

Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.

Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJ.

Pharmacotherapy. 2000 Sep;20(9):1116-9.

PMID:
10999505
43.

Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function.

Neuhauser MM, McKinnon PS, Hershberger E, Rybak MJ.

Pharmacotherapy. 2000 May;20(5):554-61.

PMID:
10809342
44.

Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside.

Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ.

Pharmacotherapy. 1999 Nov;19(11):1252-60.

PMID:
10555931
45.
46.

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments.

Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ.

Pharmacotherapy. 1999 Mar;19(3):257-66. Erratum in: Pharmacotherapy 1999 May;19(5):674.

PMID:
10221365
47.

Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.

McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW.

Clin Infect Dis. 1997 Jan;24(1):57-63.

PMID:
8994756
48.

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ.

Clin Pharmacokinet. 1995 Feb;28(2):143-60. Review.

PMID:
7736689

Supplemental Content

Loading ...
Support Center